{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["PROTACs", "Parkinson\u2019s disease", "epigenetic targets", "histone deacetylases", "inhibitors"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35625059", "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "05", "Day": "21"}], "Language": ["eng"], "ELocationID": ["672", "10.3390/brainsci12050672"], "Journal": {"ISSN": "2076-3425", "JournalIssue": {"Volume": "12", "Issue": "5", "PubDate": {"Year": "2022", "Month": "May", "Day": "21"}}, "Title": "Brain sciences", "ISOAbbreviation": "Brain Sci"}, "ArticleTitle": "Histone Deacetylases as Epigenetic Targets for Treating Parkinson's Disease.", "Abstract": {"AbstractText": ["Parkinson's disease (PD) is a chronic progressive neurodegenerative disease that is increasingly becoming a global threat to the health and life of the elderly worldwide. Although there are some drugs clinically available for treating PD, these treatments can only alleviate the symptoms of PD patients but cannot completely cure the disease. Therefore, exploring other potential mechanisms to develop more effective treatments that can modify the course of PD is still highly desirable. Over the last two decades, histone deacetylases, as an important group of epigenetic targets, have attracted much attention in drug discovery. This review focused on the current knowledge about histone deacetylases involved in PD pathophysiology and their inhibitors used in PD studies. Further perspectives related to small molecules that can inhibit or degrade histone deacetylases to treat PD were also discussed."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, School of Basic Medical Science, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Li", "ForeName": "Yan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, School of Basic Medical Science, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Gu", "ForeName": "Zhicheng", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, School of Basic Medical Science, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Lin", "ForeName": "Shuxian", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, School of Basic Medical Science, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Chen", "ForeName": "Lei", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Neurobiology, Academy of Biology and Biotechnology, Southern Federal University, Stachki Ave. 194/1, 344090 Rostov-on-Don, Russia."}], "LastName": "Dzreyan", "ForeName": "Valentina", "Initials": "V"}, {"Identifier": ["0000-0002-3554-3529"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Neurobiology, Academy of Biology and Biotechnology, Southern Federal University, Stachki Ave. 194/1, 344090 Rostov-on-Don, Russia."}], "LastName": "Eid", "ForeName": "Moez", "Initials": "M"}, {"Identifier": ["0000-0002-4245-0427"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Neurobiology, Academy of Biology and Biotechnology, Southern Federal University, Stachki Ave. 194/1, 344090 Rostov-on-Don, Russia."}], "LastName": "Demyanenko", "ForeName": "Svetlana", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, School of Basic Medical Science, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "He", "ForeName": "Bin", "Initials": "B"}], "GrantList": [{"GrantID": "no. 81960628 and 82160655", "Agency": "National Natural Science Foundation of China", "Country": ""}, {"GrantID": "no. 342 ZK[2022]035, [2020]1Y395 and [2020]4Y206", "Agency": "Guizhou Science and Technology Department of China", "Country": ""}, {"GrantID": "grant #21-345 15-00188", "Agency": "Russian Science Foundation", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Brain Sci", "NlmUniqueID": "101598646", "ISSNLinking": "2076-3425"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Vijiaratnam N., Simuni T., Bandmann O., Morris H.R., Foltynie T. Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol. 2021;20:497\u2013584. doi: 10.1016/S1474-4422(21)00061-2.", "ArticleIdList": ["10.1016/S1474-4422(21)00061-2", "34146514"]}, {"Citation": "Rocca W.A. The burden of Parkinson\u2019s disease: A worldwide perspective. Lancet Neurol. 2018;17:928\u2013929. doi: 10.1016/S1474-4422(18)30355-7.", "ArticleIdList": ["10.1016/S1474-4422(18)30355-7", "30287052"]}, {"Citation": "National Bureau of Statistics  Main Data of the Seventh National Census of China.  [(accessed on 25 April 2022)]; Available online:  http://www.stats.gov.cn/tjsj/zxfb/202105/t20210510_1817176.html."}, {"Citation": "GBD 2016 Neurology Collaborators Global, regional, and national burden of neurological disorders, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459\u2013480. doi: 10.1016/S1474-4422(18)30499-X.", "ArticleIdList": ["10.1016/S1474-4422(18)30499-X", "PMC6459001", "30879893"]}, {"Citation": "Dorsey E.R., Sherer T., Okun M.S., Bloem B.R. The emerging evidence of the Parkinson pandemic. J. Parkinsons Dis. 2018;8:S3\u2013S8. doi: 10.3233/JPD-181474.", "ArticleIdList": ["10.3233/JPD-181474", "PMC6311367", "30584159"]}, {"Citation": "Dorsey E.R., Bloem B.R. The Parkinson Pandemic-A Call to Action. JAMA Neurol. 2018;75:9\u201310. doi: 10.1001/jamaneurol.2017.3299.", "ArticleIdList": ["10.1001/jamaneurol.2017.3299", "29131880"]}, {"Citation": "Zhang K., Zhu S., Li J., Jiang T., Feng L., Pei J., Wang G., Ouyang L., Liu B. Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson\u2019s disease. Acta Pharm. Sin. B. 2021;11:3015\u20133034. doi: 10.1016/j.apsb.2021.02.016.", "ArticleIdList": ["10.1016/j.apsb.2021.02.016", "PMC8546670", "34729301"]}, {"Citation": "Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011;63:182\u2013217. doi: 10.1124/pr.110.002642.", "ArticleIdList": ["10.1124/pr.110.002642", "21303898"]}, {"Citation": "Doty R.L. Olfactory dysfunction in Parkinson disease. Nat. Rev. Neurol. 2012;8:329\u2013339.", "ArticleIdList": ["22584158"]}, {"Citation": "Santangelo R.M., Acker T.M., Zimmerman S.S., Katzman B.M., Strong K.L., Traynelis S.F., Liotta D.C. Novel NMDA receptor modulators: An update. Expert Opin. Ther. Pat. 2012;22:1337\u20131352. doi: 10.1517/13543776.2012.728587.", "ArticleIdList": ["10.1517/13543776.2012.728587", "PMC3677696", "23009122"]}, {"Citation": "Shook B.C., Jackson P.F. Adenosine A(2A) Receptor Antagonists and Parkinson\u2019s Disease. ACS Chem. Neurosci. 2011;2:555\u2013567. doi: 10.1021/cn2000537.", "ArticleIdList": ["10.1021/cn2000537", "PMC3369712", "22860156"]}, {"Citation": "Valera E., Masliah E. Therapeutic approaches in Parkinson\u2019s disease and related disorders. J. Neurochem. 2016;139((Suppl. S1)):346\u2013352. doi: 10.1111/jnc.13529.", "ArticleIdList": ["10.1111/jnc.13529", "PMC4939141", "26749150"]}, {"Citation": "McFarthing K., Buff S., Rafaloff G., Dominey T., Wyse R.K., Stott S.R. Parkinson\u2019s Disease Drug Therapies in the Clinical Trial Pipeline: 2020. J. Parkinsons Dis. 2020;10:757\u2013774. doi: 10.3233/JPD-202128.", "ArticleIdList": ["10.3233/JPD-202128", "PMC7458531", "32741777"]}, {"Citation": "McFarthing K., Rafaloff G., Baptista M.A.S., Wyse R.K., Stott S.R.W. Parkinson\u2019s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update. J. Parkinsons Dis. 2021;11:891\u2013903. doi: 10.3233/JPD-219006.", "ArticleIdList": ["10.3233/JPD-219006", "PMC8461678", "34151864"]}, {"Citation": "Berger S.L., Kouzarides T., Shiekhattar R., Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23:781\u2013783. doi: 10.1101/gad.1787609.", "ArticleIdList": ["10.1101/gad.1787609", "PMC3959995", "19339683"]}, {"Citation": "Gupta R., Ambasta R.K., Kumar P. Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders. Life Sci. 2020;243:117278. doi: 10.1016/j.lfs.2020.117278.", "ArticleIdList": ["10.1016/j.lfs.2020.117278", "31926248"]}, {"Citation": "Gregoretti I.V., Lee Y.M., Goodson H.V. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J. Mol. Biol. 2004;338:17\u201331. doi: 10.1016/j.jmb.2004.02.006.", "ArticleIdList": ["10.1016/j.jmb.2004.02.006", "15050820"]}, {"Citation": "Haigis M.C., Guarente L.P. Mammalian sirtuins-Emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006;20:2913\u20132921. doi: 10.1101/gad.1467506.", "ArticleIdList": ["10.1101/gad.1467506", "17079682"]}, {"Citation": "Li Y., Wang F., Chen X., Wang J., Zhao Y., Li Y., He B. Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups. Curr. Top. Med. Chem. 2019;19:223\u2013241. doi: 10.2174/1568026619666190122144949.", "ArticleIdList": ["10.2174/1568026619666190122144949", "30674261"]}, {"Citation": "Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., Chiao J.H., Reilly J.F., Ricker J.L., Richon V.M., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood. 2007;109:31\u201339. doi: 10.1182/blood-2006-06-025999.", "ArticleIdList": ["10.1182/blood-2006-06-025999", "PMC1785068", "16960145"]}, {"Citation": "Piekarz R.L., Frye R., Turner M., Wright J.J., Allen S., Kirschbaum M.H., Zain J., Prince H.M., Leonard J.P., Geskin L.J., et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 2009;27:5410\u20135417. doi: 10.1200/JCO.2008.21.6150.", "ArticleIdList": ["10.1200/JCO.2008.21.6150", "PMC2773225", "19826128"]}, {"Citation": "Poole R.M. Belinostat: First global approval. Drugs. 2014;74:1543\u20131554. doi: 10.1007/s40265-014-0275-8.", "ArticleIdList": ["10.1007/s40265-014-0275-8", "25134672"]}, {"Citation": "Garnock-Jones K.P. Panobinostat: First global approval. Drugs. 2015;75:695\u2013704. doi: 10.1007/s40265-015-0388-8.", "ArticleIdList": ["10.1007/s40265-015-0388-8", "25837990"]}, {"Citation": "Li Y., Chen K., Zhou Y., Xiao Y., Deng M., Jiang Z., Ye W., Wang X., Wei X., Li J., et al. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor. Curr. Cancer Drug Targets. 2015;15:493\u2013503. doi: 10.2174/156800961506150805153230.", "ArticleIdList": ["10.2174/156800961506150805153230", "26282548"]}, {"Citation": "Rodrigue D.A., Pinheiro P.S.M., Sagrillo F.S., Bolognesi M.L., Fraga C.A.M. Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. Med. Res. Rev. 2020;40:2177\u20132211. doi: 10.1002/med.21701.", "ArticleIdList": ["10.1002/med.21701", "32588916"]}, {"Citation": "Yang S.S., Zhang R., Wang G., Zhang Y.-F. The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer\u2019s disease. Transl. Neurodegener. 2017;6:19. doi: 10.1186/s40035-017-0089-1.", "ArticleIdList": ["10.1186/s40035-017-0089-1", "PMC5504819", "28702178"]}, {"Citation": "Gray S.G. Targeting Huntington\u2019s disease through histone deacetylases. Clin. Epigenet. 2011;2:257\u2013277. doi: 10.1007/s13148-011-0025-7.", "ArticleIdList": ["10.1007/s13148-011-0025-7", "PMC3365382", "22704341"]}, {"Citation": "Sharma S., Taliyan R. Targeting histone deacetylases: A novel approach in Parkinson\u2019s disease. Parkinsons Dis. 2015;2015:303294. doi: 10.1155/2015/303294.", "ArticleIdList": ["10.1155/2015/303294", "PMC4324954", "25694842"]}, {"Citation": "Faraco G., Cavone L., Chiarugi A. The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol. Med. 2011;17:442\u2013447. doi: 10.2119/molmed.2011.00077.", "ArticleIdList": ["10.2119/molmed.2011.00077", "PMC3105147", "21373721"]}, {"Citation": "Raza C., Anjum R., Shakeel N.U.A. Parkinson\u2019s disease: Mechanisms, translational models and management strategies. Life Sci. 2019;226:77\u201390. doi: 10.1016/j.lfs.2019.03.057.", "ArticleIdList": ["10.1016/j.lfs.2019.03.057", "30980848"]}, {"Citation": "Kordower J.H., Olanow C.W., Dodiya H.B., Chu Y., Beach T.G., Adler C.H., Halliday G.M., Bartus R.T. Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Pt 8Brain. 2013;136:2419\u20132431. doi: 10.1093/brain/awt192.", "ArticleIdList": ["10.1093/brain/awt192", "PMC3722357", "23884810"]}, {"Citation": "Kalia L.V., Lang P.E. Parkinson\u2019s disease. Lancet. 2015;386:896\u2013912. doi: 10.1016/S0140-6736(14)61393-3.", "ArticleIdList": ["10.1016/S0140-6736(14)61393-3", "25904081"]}, {"Citation": "Peng C., Trojanowski J.Q., Lee V.M. Protein transmission in neurodegenerative disease. Nat. Rev. Neurol. 2020;16:199\u2013212. doi: 10.1038/s41582-020-0333-7.", "ArticleIdList": ["10.1038/s41582-020-0333-7", "32203399"]}, {"Citation": "Mezzaroba L., Alfieri D.F., Colado Sim\u00e3o A.N., Reiche E.M.V. The role of zinc, copper, manganese and iron in neurodegenerative diseases. Neurotoxicology. 2019;74:230\u2013241. doi: 10.1016/j.neuro.2019.07.007.", "ArticleIdList": ["10.1016/j.neuro.2019.07.007", "31377220"]}, {"Citation": "Puspita L., Chung S.Y., Shim J.W. Oxidative stress and cellular pathologies in Parkinson\u2019s disease. Mol. Brain. 2017;10:53. doi: 10.1186/s13041-017-0340-9.", "ArticleIdList": ["10.1186/s13041-017-0340-9", "PMC5706368", "29183391"]}, {"Citation": "Przedborski S. The two-century journey of Parkinson disease research. Nat. Rev. Neurosci. 2017;18:251\u2013259. doi: 10.1038/nrn.2017.25.", "ArticleIdList": ["10.1038/nrn.2017.25", "28303016"]}, {"Citation": "Abeliovich A., Gitler A.D. Defects in trafficking bridge Parkinson\u2019s disease pathology and genetics. Nature. 2016;539:207\u2013216. doi: 10.1038/nature20414.", "ArticleIdList": ["10.1038/nature20414", "27830778"]}, {"Citation": "Thomas E.A., D\u2019Mello S.R. Complex neuroprotective and neurotoxic effects of histone deacetylases. J. Neurochem. 2018;145:96\u2013110. doi: 10.1111/jnc.14309.", "ArticleIdList": ["10.1111/jnc.14309", "PMC5920706", "29355955"]}, {"Citation": "Patnaik D., Pao P.C., Zhao W.N., Silva M.C., Hylton N.K., Chindavong P.S., Pan L., Tsai L.-H., Haggarty S.J. Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration. ACS Chem. Neurosci. 2021;12:271\u2013284. doi: 10.1021/acschemneuro.0c00308.", "ArticleIdList": ["10.1021/acschemneuro.0c00308", "33417763"]}, {"Citation": "Harrison I.F., Powell N.M., Dexter D.T. The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson\u2019s disease. J. Neurochem. 2019;148:136\u2013156. doi: 10.1111/jnc.14599.", "ArticleIdList": ["10.1111/jnc.14599", "PMC2605257", "19116652"]}, {"Citation": "Dobbin M.M., Madabhushi R., Pan L., Chen Y., Kim D., Gao J., Ahanonu B., Pao P.-C., Qiu Y., Zhao Y., et al. SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons. Nat. Neurosci. 2013;16:1008\u20131015. doi: 10.1038/nn.3460.", "ArticleIdList": ["10.1038/nn.3460", "PMC4758134", "23852118"]}, {"Citation": "Donmez G., Outeiro T.F. SIRT1 and SIRT2: Emerging targets in neurodegeneration. EMBO Mol. Med. 2013;5:344\u2013352. doi: 10.1002/emmm.201302451.", "ArticleIdList": ["10.1002/emmm.201302451", "PMC3598076", "23417962"]}, {"Citation": "Demyanenko S., Gantsgorn E., Rodkin S., Sharifulina S. Localization and Expression of Sirtuins 1, 2, 6 and Plasticity-Related Proteins in the Recovery Period after a Photothrombotic Stroke in Mice. J. Stroke Cerebrovasc. Dis. 2021;29:105152. doi: 10.1016/j.jstrokecerebrovasdis.2020.105152.", "ArticleIdList": ["10.1016/j.jstrokecerebrovasdis.2020.105152", "32912518"]}, {"Citation": "Mazzocchi M., Collins L.M., Sullivan A.M., O\u2019Keeffe G.W. The class II histone deacetylases as therapeutic targets for Parkinson\u2019s disease. Neuronal Signal. 2020;4:NS20200001. doi: 10.1042/NS20200001.", "ArticleIdList": ["10.1042/NS20200001", "PMC7373248", "32714601"]}, {"Citation": "Demyanenko S.V., Dzreyan V.A., Uzdensky A.B. Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of \u03b1-phenyl tropolone, HPOB, and sodium valproate. Brain Res. Bull. 2020;162:151\u2013165. doi: 10.1016/j.brainresbull.2020.06.010.", "ArticleIdList": ["10.1016/j.brainresbull.2020.06.010", "32592806"]}, {"Citation": "Demyanenko S., Berezhnaya E., Neginskaya M., Rodkin S., Dzreyan V., Pitinova M. Class II histone deacetylases in the post-stroke recovery period-expression, cellular, and subcellular localization-promising targets for neuroprotection. J. Cell Biochem. 2019;120:19590\u201319609. doi: 10.1002/jcb.29266.", "ArticleIdList": ["10.1002/jcb.29266", "31264264"]}, {"Citation": "Park G., Tan J., Garcia G., Kang Y., Salvesen G., Zhang Z. Regulation of Histone Acetylation by Autophagy in Parkinson Disease. J. Biol. Chem. 2016;291:3531\u20133540. doi: 10.1074/jbc.M115.675488.", "ArticleIdList": ["10.1074/jbc.M115.675488", "PMC4751393", "26699403"]}, {"Citation": "Harrison I.F., Smith A.D., Dexter D.T. Pathological histone acetylation in Parkinson\u2019s disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition. Neurosci. Lett. 2018;666:48\u201357. doi: 10.1016/j.neulet.2017.12.037.", "ArticleIdList": ["10.1016/j.neulet.2017.12.037", "PMC5821898", "29273397"]}, {"Citation": "Gebremedhin K.G., Rademacher D.J. Histone H3 acetylation in the postmortem Parkinson\u2019s disease primary motor cortex. Neurosci. Lett. 2016;627:121\u2013125. doi: 10.1016/j.neulet.2016.05.060.", "ArticleIdList": ["10.1016/j.neulet.2016.05.060", "PMC5067161", "27241718"]}, {"Citation": "Dijkstra A.A., Ingrassia A., de Menezes R.X., van Kesteren R.E., Rozemuller A.J.M., Heutink P., van de Berg W.D.J. Evidence for Immune Response, Axonal Dysfunction and Reduced Endocytosis in the Substantia Nigra in Early Stage Parkinson\u2019s Disease. PLoS ONE. 2015;10:e0128651. doi: 10.1371/journal.pone.0128651.", "ArticleIdList": ["10.1371/journal.pone.0128651", "PMC4472235", "26087293"]}, {"Citation": "Mazzocchi M., Wyatt S.L., Mercatelli D., Morari M., Morales-Prieto N., Collins L., Sullivan A.M., O\u2019Keeffe G.W. Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling. Front. Cell Dev. Biol. 2019;7:191. doi: 10.3389/fcell.2019.00191.", "ArticleIdList": ["10.3389/fcell.2019.00191", "PMC6753186", "31572723"]}, {"Citation": "Mazzocchi M., Goulding S.R., Wyatt S.L., Collins L.M., Sullivan A.M., O\u2019Keeffe G.W. LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin and \u03b1-synuclein-induced degeneration in cellular models of Parkinson\u2019s disease. Mol. Cell Neurosci. 2021;115:103642. doi: 10.1016/j.mcn.2021.103642.", "ArticleIdList": ["10.1016/j.mcn.2021.103642", "34119632"]}, {"Citation": "Taniguchi M., Carreira M.B., Cooper Y.A., Bobadilla A.-C., Heinsbroek J.A., Koike N., Larson E., Balmuth E.A., Hughes B.W., Penrod R.D., et al. HDAC5 and Its Target Gene, Npas4, Function in the Nucleus Accumbens to Regulate Cocaine-Conditioned Behaviors. Neuron. 2017;96:130\u2013144. doi: 10.1016/j.neuron.2017.09.015.", "ArticleIdList": ["10.1016/j.neuron.2017.09.015", "PMC5761688", "28957664"]}, {"Citation": "Mazzocchi M., Goulding S.R., Morales-Prieto N., Foley T., Collins L.M., Sullivan A.M., O\u2019Keeffe G.W. Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson\u2019s disease. Brain Behav. Immun. 2022;102:151\u2013160. doi: 10.1016/j.bbi.2022.02.025.", "ArticleIdList": ["10.1016/j.bbi.2022.02.025", "35217173"]}, {"Citation": "Takahashi-Fujigasaki J., Fujigasaki H. Histone deacetylase (HDAC) 4 involvement in both Lewy and Marinesco bodies. Neuropathol. Appl. Neurobiol. 2006;32:562\u2013566. doi: 10.1111/j.1365-2990.2006.00733.x.", "ArticleIdList": ["10.1111/j.1365-2990.2006.00733.x", "16972890"]}, {"Citation": "Wu Q., Yang X., Zhang L., Zhang Y., Feng L. Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Exerts Neurotoxicity in Models of Parkinson\u2019s Disease. Mol. Neurobiol. 2017;54:6970\u20136983. doi: 10.1007/s12035-016-0199-2.", "ArticleIdList": ["10.1007/s12035-016-0199-2", "27785754"]}, {"Citation": "Lang C., Campbell K.P., Ryan B.J., Carling P., Attar M., Vowles J., Perestenko O.V., Bowden R., Baig F., Kasten M., et al. Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes. Cell Stem Cell. 2019;24:93\u2013106. doi: 10.1016/j.stem.2018.10.023.", "ArticleIdList": ["10.1016/j.stem.2018.10.023", "PMC6327112", "30503143"]}, {"Citation": "Cho Y., Cavalli V. HDAC5 is a novel injury-regulated tubulin deacetylase controlling axon regeneration. EMBO J. 2012;31:3063\u20133078. doi: 10.1038/emboj.2012.160.", "ArticleIdList": ["10.1038/emboj.2012.160", "PMC3400015", "22692128"]}, {"Citation": "Cho Y., Sloutsky R., Naegle K.M., Cavalli V. Injury-induced HDAC5 nuclear export is essential for axon regeneration [published correction appears in Cell. Cell. 2013;155:894\u2013908. doi: 10.1016/j.cell.2013.10.004.", "ArticleIdList": ["10.1016/j.cell.2013.10.004", "PMC3987749", "24209626"]}, {"Citation": "Collins L.M., Adriaanse L.J., Theratile S.D., Hegarty S.V., Sullivan A., O\u2019Keeffe G.W. Class-IIa Histone Deacetylase Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult. Mol. Neurobiol. 2015;51:1432\u20131442. doi: 10.1007/s12035-014-8820-8.", "ArticleIdList": ["10.1007/s12035-014-8820-8", "25065734"]}, {"Citation": "Akase K., Oda S., Kuroda M., Funato H. Monoaminergic and neuropeptidergic neurons have distinct expression profiles of histone deacetylases. PLoS ONE. 2013;8:e58473.", "ArticleIdList": ["PMC3587588", "23469282"]}, {"Citation": "Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., Yao T. -P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115:727\u2013738. doi: 10.1016/S0092-8674(03)00939-5.", "ArticleIdList": ["10.1016/S0092-8674(03)00939-5", "14675537"]}, {"Citation": "Richter-Landsberg C., Leyk J. Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration. Acta Neuropathol. 2013;126:793\u2013807. doi: 10.1007/s00401-013-1158-x.", "ArticleIdList": ["10.1007/s00401-013-1158-x", "23912309"]}, {"Citation": "Du G., Liu X., Chen X., Song M., Yan Y., Jiao R., Wang C. -C. Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation. Mol. Biol. Cell. 2010;21:2128\u20132137. doi: 10.1091/mbc.e10-03-0200.", "ArticleIdList": ["10.1091/mbc.e10-03-0200", "PMC2893978", "20444973"]}, {"Citation": "Du Y., Wang F., Zou J., Le W., Dong Q., Wang Z., Shen F., Yu L., Li Y. Histone deacetylase 6 regulates cytotoxic \u03b1-synuclein accumulation through induction of the heat shock response. Neurobiol. Aging. 2014;35:2316\u20132328. doi: 10.1016/j.neurobiolaging.2014.04.029.", "ArticleIdList": ["10.1016/j.neurobiolaging.2014.04.029", "24866403"]}, {"Citation": "Pais\u00e1n-Ru\u00edz C., Jain S., Evans E.W., Gilks W.P., Sim\u00f3n J., van der Brug M., de Munain A.L., Aparicio S., Gil A.M., Khan N., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease. Neuron. 2004;44:595\u2013600. doi: 10.1016/j.neuron.2004.10.023.", "ArticleIdList": ["10.1016/j.neuron.2004.10.023", "15541308"]}, {"Citation": "Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601\u2013607. doi: 10.1016/j.neuron.2004.11.005.", "ArticleIdList": ["10.1016/j.neuron.2004.11.005", "15541309"]}, {"Citation": "Gilks W.P., Abou-Sleima P.M., Gandhi S., Jain S., Singleton A., Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., et al. A common LRRK2 mutation in idiopathic Parkinson\u2019s disease. Lancet. 2005;365:415\u2013416. doi: 10.1016/S0140-6736(05)17830-1.", "ArticleIdList": ["10.1016/S0140-6736(05)17830-1", "15680457"]}, {"Citation": "Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., Kawaguchi T., Tsunoda T., Watanabe M., Takeda A., et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson\u2019s disease. Nat. Genet. 2009;41:1303\u20131307. doi: 10.1038/ng.485.", "ArticleIdList": ["10.1038/ng.485", "19915576"]}, {"Citation": "Sim\u00f3n-S\u00e1nchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., et al. Genome-wide association study reveals genetic risk underlying Parkinson\u2019s disease. Nat. Genet. 2009;41:1308\u20131312. doi: 10.1038/ng.487.", "ArticleIdList": ["10.1038/ng.487", "PMC2787725", "19915575"]}, {"Citation": "Godena V.K., Brookes-Hocking N., Moller A., Shaw G., Oswald M., Sancho R.M., Miller C., Whitworth A.J., De Vos K. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat. Commun. 2014;5:5245. doi: 10.1038/ncomms6245.", "ArticleIdList": ["10.1038/ncomms6245", "PMC4208097", "25316291"]}, {"Citation": "Pinho B.R., Reis S.D., Guedes-Dias P., Leit\u00e3o-Rocha A., Quintas C., Valent\u00e3o P., Andrade P., Santos M., Oliveira J.M. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson\u2019s disease. Pharmacol. Res. 2016;103:328\u2013339. doi: 10.1016/j.phrs.2015.11.024.", "ArticleIdList": ["10.1016/j.phrs.2015.11.024", "26657418"]}, {"Citation": "Jian W., Wei X., Che L., Wang Z., Sun Y., Zhu S., Lou H., Yan S., Li X., Zhou J., et al. Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury. Neurosci. Lett. 2017;658:114\u2013120. doi: 10.1016/j.neulet.2017.08.029.", "ArticleIdList": ["10.1016/j.neulet.2017.08.029", "28823893"]}, {"Citation": "Pfister J.A., Ma C., Morrison B.E., D\u2019Mello S.R. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS ONE. 2008;3:e4090. doi: 10.1371/journal.pone.0004090.", "ArticleIdList": ["10.1371/journal.pone.0004090", "PMC2605257", "19116652"]}, {"Citation": "Donmez G. The neurobiology of sirtuins and their role in neurodegeneration. Trends Pharmacol. Sci. 2012;33:494\u2013501. doi: 10.1016/j.tips.2012.05.007.", "ArticleIdList": ["10.1016/j.tips.2012.05.007", "22749331"]}, {"Citation": "Liu L., Peritore C., Ginsberg J., Shih J., Arun S., Donmez G. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson\u2019s disease. Behav. Brain Res. 2015;281:215\u2013221. doi: 10.1016/j.bbr.2014.12.035.", "ArticleIdList": ["10.1016/j.bbr.2014.12.035", "25541039"]}, {"Citation": "Zheng B., Liao Z., Locascio J.J., Lesniak K.A., Roderick S.S., Watt M.L., Eklund A.C., Zhang-James Y., Kim P.D., Hauser M.A., et al. PGC-1\u03b1, a potential therapeutic target for early intervention in Parkinson\u2019s disease. Sci. Transl. Med. 2010;2:52\u201373. doi: 10.1126/scitranslmed.3001059.", "ArticleIdList": ["10.1126/scitranslmed.3001059", "PMC3129986", "20926834"]}, {"Citation": "Austin S., St-Pierre J. PGC1\u03b1 and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders. Pt 21J. Cell Sci. 2012;125:4963\u20134971. doi: 10.1242/jcs.113662.", "ArticleIdList": ["10.1242/jcs.113662", "23277535"]}, {"Citation": "Chen Y., Jiang Y., Yang Y., Huang X., Sun C. SIRT1 Protects Dopaminergic Neurons in Parkinson\u2019s Disease Models via PGC-1\u03b1-Mediated Mitochondrial Biogenesis. Neurotox. Res. 2021;39:1393\u20131404. doi: 10.1007/s12640-021-00392-4.", "ArticleIdList": ["10.1007/s12640-021-00392-4", "34251648"]}, {"Citation": "Donmez G., Arun A., Chung C.Y., McLean P.J., Lindquist S., Guarente L. SIRT1 Protects against \u03b1-Synuclein Aggregation by Activating Molecular Chaperones. J. Neurosci. 2016;36:4138. doi: 10.1523/JNEUROSCI.3442-11.2012.", "ArticleIdList": ["10.1523/JNEUROSCI.3442-11.2012", "PMC3263206", "22219275"]}, {"Citation": "Liu L., Arun A., Ellis L., Peritore C., Donmez G. Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein. J. Biol. Chem. 2013;288:24163. doi: 10.1074/jbc.A113.403048.", "ArticleIdList": ["10.1074/jbc.A113.403048", "PMC3745361", "23956326"]}, {"Citation": "Singh A.P., Ramana G., Bajaj T., Singh V., Dwivedi S., Behari M., Dey A.B., Dey S. Elevated Serum SIRT 2 May Differentiate Parkinson\u2019s Disease From Atypical Parkinsonian Syndromes. Front. Mol. Neurosci. 2019;12:129. doi: 10.3389/fnmol.2019.00129.", "ArticleIdList": ["10.3389/fnmol.2019.00129", "PMC6581755", "31244600"]}, {"Citation": "Kazantsev A.G., Kolchinsky A.M. Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch. Neurol. 2008;65:1577\u20131581. doi: 10.1001/archneur.65.12.1577.", "ArticleIdList": ["10.1001/archneur.65.12.1577", "19064744"]}, {"Citation": "Portran D., Schaedel L., Xu Z., Th\u00e9ry M., Nachury M.V. Tubulin acetylation protects long-lived microtubules against mechanical ageing. Nat. Cell Biol. 2017;19:391\u2013398. doi: 10.1038/ncb3481.", "ArticleIdList": ["10.1038/ncb3481", "PMC5376231", "28250419"]}, {"Citation": "Garske A.L., Smith B.C., Denu J.M. Linking SIRT2 to Parkinson\u2019s disease. ACS Chem. Biol. 2007;2:529\u2013532. doi: 10.1021/cb700160d.", "ArticleIdList": ["10.1021/cb700160d", "17708669"]}, {"Citation": "Singh A.P., Nigam L., Yadav Y., Shekhar S., Subbarao N., Dey S. Design and in vitro analysis of SIRT2 inhibitor targeting Parkinson\u2019s disease. Mol. Divers. 2021;25:2261\u20132270. doi: 10.1007/s11030-020-10116-z.", "ArticleIdList": ["10.1007/s11030-020-10116-z", "32591930"]}, {"Citation": "Outeiro T.F., Kontopoulos E., Altman S.M., Kufareva I., Strathearn K.E., Amore A.M., Volk C.B., Maxwell M.M., Rochet J.-C., McLean P.J., et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson\u2019s disease. Science. 2007;317:516\u2013519. doi: 10.1126/science.1143780.", "ArticleIdList": ["10.1126/science.1143780", "17588900"]}, {"Citation": "Mohd Murshid N., Aminullah Lubis F., Makpol S. Epigenetic Changes and Its Intervention in Age-Related Neurodegenerative Diseases. Cell Mol. Neurobiol. 2022;42:577\u2013595. doi: 10.1007/s10571-020-00979-z.", "ArticleIdList": ["10.1007/s10571-020-00979-z", "33074454"]}, {"Citation": "Wang R., Sun H., Wang G., Ren H. Imbalance of Lysine Acetylation Contributes to the Pathogenesis of Parkinson\u2019s Disease. Int. J. Mol. Sci. 2020;21:7182. doi: 10.3390/ijms21197182.", "ArticleIdList": ["10.3390/ijms21197182", "PMC7582258", "33003340"]}, {"Citation": "Teijido O., Cacabelos R. Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer\u2019s and Parkinson\u2019s Diseases. Int. J. Mol. Sci. 2018;19:3199. doi: 10.3390/ijms19103199.", "ArticleIdList": ["10.3390/ijms19103199", "PMC6213964", "30332838"]}, {"Citation": "Harrison I.F., Dexter D.T. Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson\u2019s disease? Pharmacol. Ther. 2013;140:34\u201352. doi: 10.1016/j.pharmthera.2013.05.010.", "ArticleIdList": ["10.1016/j.pharmthera.2013.05.010", "23711791"]}, {"Citation": "Wu X., Chen P.S., Dallas S., Wilson B., Block M.L., Wang C.-C., Kinyamu H., Lu N., Gao X., Leng, Y., et al. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacol. 2008;11:1123\u20131134. doi: 10.1017/S1461145708009024.", "ArticleIdList": ["10.1017/S1461145708009024", "PMC2579941", "18611290"]}, {"Citation": "Chen P.S., Wang C.C., Bortner C.D., Peng G.-S., Wu X., Pang H., Lu R.-B., Gean P.-W., Chuang D.-M., Hong J.-S. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience. 2007;149:203\u2013212. doi: 10.1016/j.neuroscience.2007.06.053.", "ArticleIdList": ["10.1016/j.neuroscience.2007.06.053", "PMC2741413", "17850978"]}, {"Citation": "Kidd S.K., Schneider J.S. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Neuroscience. 2011;194:189\u2013194. doi: 10.1016/j.neuroscience.2011.08.010.", "ArticleIdList": ["10.1016/j.neuroscience.2011.08.010", "PMC3196607", "21846494"]}, {"Citation": "Harrison I.F., Crum W.R., Vernon A.C., Dexter D.T. Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson\u2019s is associated with histone acetylation and up-regulation of neurotrophic factors. Br. J. Pharmacol. 2015;172:4200\u20134215. doi: 10.1111/bph.13208.", "ArticleIdList": ["10.1111/bph.13208", "PMC4543623", "26040297"]}, {"Citation": "Kim T., Song S., Park Y., Kang S., Seo H. HDAC Inhibition by Valproic Acid Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G Transgenic Mice. Exp. Neurobiol. 2019;28:504\u2013515. doi: 10.5607/en.2019.28.4.504.", "ArticleIdList": ["10.5607/en.2019.28.4.504", "PMC6751862", "31495079"]}, {"Citation": "Hsu S.W., Hsu P.C., Chang W.S., Yu C., Wang Y., Yang J., Tsai F., Chen K., Tsai C., Bau D. Protective effects of valproic acid on 6-hydroxydopamine-induced neuroinjury. Environ. Toxicol. 2020;35:840\u2013848. doi: 10.1002/tox.22920.", "ArticleIdList": ["10.1002/tox.22920", "32167238"]}, {"Citation": "Rane P., Shields J., Heffernan M., Guo Y., Akbarian S., King J.A. The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacology. 2012;62:2409\u20132412. doi: 10.1016/j.neuropharm.2012.01.026.", "ArticleIdList": ["10.1016/j.neuropharm.2012.01.026", "22353286"]}, {"Citation": "Sharma S., Taliyan R., Singh S. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity. Behav. Brain Res. 2015;291:306\u2013314. doi: 10.1016/j.bbr.2015.05.052.", "ArticleIdList": ["10.1016/j.bbr.2015.05.052", "26048426"]}, {"Citation": "Getachew B., Csoka A.B., Bhatti A., Copeland R.L., Tizabi Y. Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson\u2019s Disease. Neurotox. Res. 2020;38:596\u2013602. doi: 10.1007/s12640-020-00238-5.", "ArticleIdList": ["10.1007/s12640-020-00238-5", "PMC7484007", "32572814"]}, {"Citation": "St Laurent R., O\u2019Brien L.M., Ahmad S.T. Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson\u2019s disease. Neuroscience. 2013;246:382\u2013390. doi: 10.1016/j.neuroscience.2013.04.037.", "ArticleIdList": ["10.1016/j.neuroscience.2013.04.037", "PMC3721507", "23623990"]}, {"Citation": "Gardian G., Yang L., Cleren C., Calingasan N.Y., Klivenyi P., Beal M.F. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromol. Med. 2004;5:235\u2013241. doi: 10.1385/NMM:5:3:235.", "ArticleIdList": ["10.1385/NMM:5:3:235", "15626823"]}, {"Citation": "Zhou W., Bercury K., Cummiskey J., Luong N., Lebin J., Freed C.R. Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J. Biol. Chem. 2011;286:14941\u201314951. doi: 10.1074/jbc.M110.211029.", "ArticleIdList": ["10.1074/jbc.M110.211029", "PMC3083206", "21372141"]}, {"Citation": "Guo Z., Zhang Z., Wang Q., Zhang J., Wang L., Zhang Q., Li H., Wu S. Manganese chloride induces histone acetylation changes in neuronal cells: Its role in manganese-induced damage. Neurotoxicology. 2018;65:255\u2013263. doi: 10.1016/j.neuro.2017.11.003.", "ArticleIdList": ["10.1016/j.neuro.2017.11.003", "29155171"]}, {"Citation": "Wang Y., Wang X., Liu L., Wang X. HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells. Neurosci. Lett. 2009;467:212\u2013216. doi: 10.1016/j.neulet.2009.10.037.", "ArticleIdList": ["10.1016/j.neulet.2009.10.037", "19835929"]}, {"Citation": "Zhu M., Li W.W., Lu C.Z. Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+ CNS. Neurosci. Ther. 2014;20:308\u2013316. doi: 10.1111/cns.12217.", "ArticleIdList": ["10.1111/cns.12217", "PMC6493005", "24351065"]}, {"Citation": "Suo H., Wang P., Tong J., Cai L., Liu J., Huang D., Huang L., Wang Z., Huang Y., Xu J., et al. NRSF is an essential mediator for the neuroprotection of trichostatin A in the MPTP mouse model of Parkinson\u2019s disease. Neuropharmacology. 2015;99:67\u201378. doi: 10.1016/j.neuropharm.2015.07.015.", "ArticleIdList": ["10.1016/j.neuropharm.2015.07.015", "26188143"]}, {"Citation": "Chen S.H., Wu H.M., Ossola B., Schendzielorz N., Wilson B., Chu C., Chen S., Wang Q., Zhang D., Qian L., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br. J. Pharmacol. 2012;165:494\u2013505. doi: 10.1111/j.1476-5381.2011.01575.x.", "ArticleIdList": ["10.1111/j.1476-5381.2011.01575.x", "PMC3268201", "21726209"]}, {"Citation": "Kidd S.K., Schneider J.S. Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res. 2010;1354:172\u2013178. doi: 10.1016/j.brainres.2010.07.041.", "ArticleIdList": ["10.1016/j.brainres.2010.07.041", "PMC2941155", "20654591"]}, {"Citation": "Johnston T.H., Huot P., Damude S., Fox S.H., Jones S.W., Rusche J.R., Brotchie J. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept study. Parkinsonism Relat. Disord. 2013;19:260\u2013264. doi: 10.1016/j.parkreldis.2012.07.001.", "ArticleIdList": ["10.1016/j.parkreldis.2012.07.001", "22901956"]}, {"Citation": "Choong C.J., Sasaki T., Hayakawa H., Yasuda T., Baba K., Hirata Y., Uesato S., Mochizuki H. A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson\u2019s disease. Neurobiol. Aging. 2016;37:103\u2013116. doi: 10.1016/j.neurobiolaging.2015.10.001.", "ArticleIdList": ["10.1016/j.neurobiolaging.2015.10.001", "26545632"]}, {"Citation": "Hirata Y., Sasaki T., Kanki H., Choong C.-J., Nishiyama K., Kubo G., Hotei A., Taniguchi M., Mochizuki H., Uesato S. New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death. Sci. Rep. 2018;8:1400. doi: 10.1038/s41598-018-19664-9.", "ArticleIdList": ["10.1038/s41598-018-19664-9", "PMC5780423", "29362442"]}, {"Citation": "Formisano L., Guida N., Laudati G., Mascolo L., Di Renzo G., Canzoniero L.M.T. MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter. J. Pharmacol. Exp. Ther. 2015;352:236\u2013243. doi: 10.1124/jpet.114.219345.", "ArticleIdList": ["10.1124/jpet.114.219345", "25467131"]}, {"Citation": "Jiang Q., Ren Y., Feng J. Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome. J. Neurosci. 2008;28:12993\u201313002. doi: 10.1523/JNEUROSCI.2860-08.2008.", "ArticleIdList": ["10.1523/JNEUROSCI.2860-08.2008", "PMC2680492", "19036992"]}, {"Citation": "Francelle L., Outeiro T.F., Rappold G.A. Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity. Sci. Rep. 2020;10:6064. doi: 10.1038/s41598-020-62678-5.", "ArticleIdList": ["10.1038/s41598-020-62678-5", "PMC7142125", "32269243"]}, {"Citation": "Yan S., Wei X., Jian W., Qin Y., Liu J., Zhu S., Jiang F., Lou H., Zhang B. Pharmacological Inhibition of HDAC6 Attenuates NLRP3 Inflammatory Response and Protects Dopaminergic Neurons in Experimental Models of Parkinson\u2019s Disease. Front. Aging Neurosci. 2020;12:78. doi: 10.3389/fnagi.2020.00078.", "ArticleIdList": ["10.3389/fnagi.2020.00078", "PMC7137996", "32296327"]}, {"Citation": "Li B., Yang Y., Wang Y., Zhang J., Ding J., Liu X., Jin Y., Lian B., Ling Y., Sun C. Acetylation of NDUFV1 induced by a newly synthesized HDAC6 inhibitor HGC rescues dopaminergic neuron loss in Parkinson models. iScience. 2021;24:102302. doi: 10.1016/j.isci.2021.102302.", "ArticleIdList": ["10.1016/j.isci.2021.102302", "PMC8022854", "33851105"]}, {"Citation": "El-Saiy K.A., Sayed R.H., El-Sahar A.E., Kandil E.A. Modulation of histone deacetylase, the ubiquitin proteasome system, and autophagy underlies the neuroprotective effects of venlafaxine in a rotenone-induced Parkinson\u2019s disease model in rats. Chem. Biol. Interact. 2022;354:109841. doi: 10.1016/j.cbi.2022.109841.", "ArticleIdList": ["10.1016/j.cbi.2022.109841", "35104487"]}, {"Citation": "Zhang Y., Yan J., Yao T.P. Discovery of a fluorescent probe with HDAC6 selective inhibition. Eur. J. Med. Chem. 2017;141:596\u2013602. doi: 10.1016/j.ejmech.2017.10.022.", "ArticleIdList": ["10.1016/j.ejmech.2017.10.022", "PMC5694690", "29102179"]}, {"Citation": "Strebl M.G., Campbell A.J., Zhao W.N., Schroeder F.A., Riley M.M., Chindavong P.S., Morin T.M., Haggarty S.J., Wagner F.F., Ritter T., et al. HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination. ACS Cent. Sci. 2017;3:1006\u20131014. doi: 10.1021/acscentsci.7b00274.", "ArticleIdList": ["10.1021/acscentsci.7b00274", "PMC5620987", "28979942"]}, {"Citation": "Tago T., Toyohara J., Ishi K. Preclinical Evaluation of an 18F-Labeled SW-100 Derivative for PET Imaging of Histone Deacetylase 6 in the Brain. ACS Chem. Neurosci. 2021;12:746\u2013755. doi: 10.1021/acschemneuro.0c00774.", "ArticleIdList": ["10.1021/acschemneuro.0c00774", "33502174"]}, {"Citation": "Nie H., Hong Y., Lu X., Zhang J., Chen H., Li Y., Ma Y., Ying W. SIRT2 mediates oxidative stress-induced apoptosis of differentiated PC12 cells. Neuroreport. 2014;25:838\u2013842. doi: 10.1097/WNR.0000000000000192.", "ArticleIdList": ["10.1097/WNR.0000000000000192", "24922350"]}, {"Citation": "She D.T., Wong L.J., Baik S.H., Arumugam T.V. SIRT2 Inhibition Confers Neuroprotection by Downregulation of FOXO3a and MAPK Signaling Pathways in Ischemic Stroke. Mol. Neurobiol. 2018;55:9188\u20139203. doi: 10.1007/s12035-018-1058-0.", "ArticleIdList": ["10.1007/s12035-018-1058-0", "29654491"]}, {"Citation": "Chopra V., Quinti L., Kim J., Vollor L., Narayanan K.L., Edgerly C., Cipicchio P.M., Lauver M.A., Choi S.H., Silverman R.B., et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington\u2019s disease mouse models. Cell Rep. 2012;2:1492\u20131497. doi: 10.1016/j.celrep.2012.11.001.", "ArticleIdList": ["10.1016/j.celrep.2012.11.001", "PMC3534897", "23200855"]}, {"Citation": "Szeg\u0151 \u00c9.M., Gerhardt E., Outeiro T.E. Sirtuin 2 enhances dopaminergic differentiation via the AKT/GSK-3\u03b2/\u03b2-catenin pathway. Neurobiol. Aging. 2017;56:7\u201316. doi: 10.1016/j.neurobiolaging.2017.04.001.", "ArticleIdList": ["10.1016/j.neurobiolaging.2017.04.001", "28478325"]}, {"Citation": "Wang X., Wang M., Yang L., Yang L., Bai J., Yan Z., Zhang Y. Inhibition of Sirtuin 2 exerts neuroprotection in aging rats with increased neonatal iron intake. Neural Regen. Res. 2014;9:1917\u20131922.", "ArticleIdList": ["PMC4281432", "25558243"]}, {"Citation": "Guan Q., Wang M., Chen H., Yang L., Yan Z., Wang X. Aging-related 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurochemial and behavioral deficits and redox dysfunction: Improvement by AK-7. Exp. Gerontol. 2016;82:19\u201329. doi: 10.1016/j.exger.2016.05.011.", "ArticleIdList": ["10.1016/j.exger.2016.05.011", "27235848"]}, {"Citation": "Chen X., Wales P., Quinti L., Zuo F., Moniot S., H\u00e9risson F., Rauf N.A., Wang H., Silverman R.B., Ayata C., et al. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson\u2019s disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLoS ONE. 2015;10:e0116919. doi: 10.1371/journal.pone.0116919.", "ArticleIdList": ["10.1371/journal.pone.0116919", "PMC4301865", "25608039"]}, {"Citation": "Di Fruscia P., Zacharioudakis E., Liu C., Moniot S., Laohasinnarong S., Khongkow M., Harrison I.F., Koltsida K., Reynolds C.R., Schmidtkunz K., et al. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson\u2019s disease model. Chem. Med. Chem. 2015;10:69\u201382. doi: 10.1002/cmdc.201402431.", "ArticleIdList": ["10.1002/cmdc.201402431", "25395356"]}, {"Citation": "Ai T., Wilson D.J., More S.S., Xie J., Chen L. 5-((3-Amidobenzyl) oxy) nicotinamides as Sirtuin 2 Inhibitors. J. Med. Chem. 2016;59:2928\u20132941. doi: 10.1021/acs.jmedchem.5b01376.", "ArticleIdList": ["10.1021/acs.jmedchem.5b01376", "26982234"]}, {"Citation": "Choi S.H., Quinti L., Kazantsev A.G., Silverman R.B. 3-(N-arylsulfamoyl) benzamides, inhibitors of human sirtuin type 2 (SIRT2) Bioorg. Med. Chem. Lett. 2012;22:2789\u20132793. doi: 10.1016/j.bmcl.2012.02.089.", "ArticleIdList": ["10.1016/j.bmcl.2012.02.089", "PMC3326608", "22446090"]}, {"Citation": "Wu J.Y., Niu F.N., Huang R., Xu Y. Enhancement of glutamate uptake in 1-methyl-4-phenylpyridinium-treated astrocytes by trichostatin A. Neuroreport. 2008;19:1209\u20131212. doi: 10.1097/WNR.0b013e328308b355.", "ArticleIdList": ["10.1097/WNR.0b013e328308b355", "18628666"]}, {"Citation": "Yang K., Zhao Y., Nie X., Wu H., Wang B., Almodovar-Rivera C.M., Xie H., Tang W. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders. Cell Chem. Biol. 2020;27:866\u2013876.e8. doi: 10.1016/j.chembiol.2020.04.008.", "ArticleIdList": ["10.1016/j.chembiol.2020.04.008", "PMC7368820", "32413286"]}, {"Citation": "Sandi C., Pinto R.M., Al-Mahdawi S., Ezzatizadeh V., Barnes G., Jones S., Rusche J.R., Gottesfeld J., Pook M.A. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis. 2011;42:496\u2013505. doi: 10.1016/j.nbd.2011.02.016.", "ArticleIdList": ["10.1016/j.nbd.2011.02.016", "PMC3107941", "21397024"]}, {"Citation": "Wang C., Zheng C., Wang H., Zhang L., Liu Z., Xu P. The state of the art of PROTAC technologies for drug discovery. Eur. J. Med. Chem. 2022;235:114290. doi: 10.1016/j.ejmech.2022.114290.", "ArticleIdList": ["10.1016/j.ejmech.2022.114290", "35307618"]}, {"Citation": "Kumar D., Hassan M.I. Targeted protein degraders march towards the clinic for neurodegenerative diseases. Ageing Res. Rev. 2022;78:101616. doi: 10.1016/j.arr.2022.101616.", "ArticleIdList": ["10.1016/j.arr.2022.101616", "35378298"]}, {"Citation": "Cao Z., Gu Z., Lin S.X., Chen D., Wang J., Zhao Y., Li Y., Liu T., Li Y., Wang Y., et al. Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6. ACS Chem. Biol. 2021;16:2746\u20132751. doi: 10.1021/acschembio.1c00681.", "ArticleIdList": ["10.1021/acschembio.1c00681", "34860497"]}, {"Citation": "Yang K., Wu H., Zhang Z., Leisten E.D., Nie X., Liu B., Wen Z., Zhang J., Cunningham M.D., Tang W. Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. ACS Med. Chem. Lett. 2020;11:575\u2013581. doi: 10.1021/acsmedchemlett.0c00046.", "ArticleIdList": ["10.1021/acsmedchemlett.0c00046", "PMC7153272", "32292566"]}, {"Citation": "Yang H., Lv W., He M., Deng H., Li H., Wu W., Rao Y. Plasticity in designing PROTACs for selective and potent degradation of HDAC6. Chem. Commun. 2019;55:14848\u201314851. doi: 10.1039/C9CC08509B.", "ArticleIdList": ["10.1039/C9CC08509B", "31769449"]}, {"Citation": "An Z., Lv W., Su S., Wu W., Rao Y. Developing potent PROTACs tools for selective degradation of HDAC6 protein. Protein Cell. 2019;10:606\u2013609. doi: 10.1007/s13238-018-0602-z.", "ArticleIdList": ["10.1007/s13238-018-0602-z", "PMC6626596", "30603959"]}, {"Citation": "Wu H., Yang K., Zhang Z., Leisten E.D., Li Z., Xie H., Liu J., Smith K.A., Novakova Z., Barinka C., et al. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity. J. Med. Chem. 2019;62:7042\u20137057. doi: 10.1021/acs.jmedchem.9b00516.", "ArticleIdList": ["10.1021/acs.jmedchem.9b00516", "31271281"]}, {"Citation": "Yang K., Song Y., Xie H., Wu H., Wu Y.-T., Leisten E.D., Tang W. Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. Bioorg. Med. Chem. Lett. 2018;28:2493\u20132497. doi: 10.1016/j.bmcl.2018.05.057.", "ArticleIdList": ["10.1016/j.bmcl.2018.05.057", "29871848"]}, {"Citation": "Hong J.Y., Jing H., Price I.R., Cao J., Bai J.J., Lin H. Simultaneous Inhibition of SIRT2 Deacetylase and Defatty-Acylase Activities via a PROTAC Strategy. ACS. Med. Chem. Lett. 2020;11:2305\u20132311. doi: 10.1021/acsmedchemlett.0c00423.", "ArticleIdList": ["10.1021/acsmedchemlett.0c00423", "PMC7667848", "33214845"]}, {"Citation": "Schiedel M., Lehotzky A., Szunyogh S., Ol\u00e1h J., Hammelmann S., W\u00f6ssner N., Robaa D., Einsle O., Sippl W., Ov\u00e1d J., et al. HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for the Development of Proteolysis-Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)*. Chembiochem. 2020;21:3371\u20133376. doi: 10.1002/cbic.202000351.", "ArticleIdList": ["10.1002/cbic.202000351", "PMC7754454", "32672888"]}, {"Citation": "Schiedel M., Herp D., Hammelmann S., Swyter S., Lehotzky A., Robaa D., Ol\u00e1h J., Ov\u00e1di J., Sippl W., Jung M. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals) J. Med. Chem. 2018;61:482\u2013491. doi: 10.1021/acs.jmedchem.6b01872.", "ArticleIdList": ["10.1021/acs.jmedchem.6b01872", "28379698"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "4", "Day": "26"}, {"Year": "2022", "Month": "5", "Day": "17"}, {"Year": "2022", "Month": "5", "Day": "19"}, {"Year": "2022", "Month": "5", "Day": "28", "Hour": "1", "Minute": "4"}, {"Year": "2022", "Month": "5", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "29", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "5", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["35625059", "PMC9140162", "10.3390/brainsci12050672", "brainsci12050672"]}}], "PubmedBookArticle": []}